Abstract
AbstractMajor depressive disorder (MDD) is a prevalent and debilitating psychiatric disease that leads to substantial loss of quality of life. There has been little progress in developing new MDD therapeutics due to a poor understanding of disease heterogeneity and individuals’ responses to treatments. Electroencephalography (EEG) is poised to improve this, owing to the ease of large-scale data collection and the advancement of computational methods to address artifacts. This review summarizes the viability of EEG for developing brain-based biomarkers in MDD. We examine the properties of well-established EEG preprocessing pipelines and consider factors leading to the discovery of sensitive and reliable biomarkers.
Publisher
Springer Science and Business Media LLC
Reference98 articles.
1. Belmaker, R. H. & Agam, G. Major depressive disorder. N. Engl. J. Med. 358, 55–68 (2008).
2. Greenberg, P. E. et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). PharmacoEconomics 39, 653–665 (2021).
3. Carhart-Harris, R. L. et al. Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Sci. Rep. 7, 1 (2017).
4. Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78, 481–489 (2021).
5. Yavi, M., Lee, H., Henter, I. D., Park, L. T. & Zarate, C. A. Ketamine treatment for depression: a review. Discov. Mental Health 2, 9 (2022).